OBJECTIVES: To investigate the prognosis of advanced liver cancer patients treated with CIK-DCs and the mechanism of apoptosis of HEPG 2 cells. METHODS: 67 patients were enrolled in the study. Peripheral blood mononuclear cells (PBMCs) were separated, of which adherent PBMCs used granulocyte 2 macrophage colony2 stimulating factor (GM2CSF), tumor necrosis factor 2α (TNF2α), and interleukin 24 (IL24) to induce DCs, which were sensitized with antigen of autologous or exogenous cancer cells to obtain Ag-DCs; suspended PBMCs used interferon 2γ (IFN2γ), IL-2, and CD 3 monoclonal antibody (CD3mAb) respectively, to induce CIK cells. DCs and CIK cells were cultured together. Flow cytometry was used to detect the phenotypes of DCs and CIK cells, and the blood retransfused into patients. Western blot and flow cytometer were used to analyze the growth cycle of HepG 2 cells and the expression of BAX and PCNA. RESULTS: No patients underwent complete remission, 5 obtained partial remission and 29 had stable disease. Of the 31 patients whose lesions could not be evaluated, 17 received effective treatment, showing that the immune response was enhanced. In vitro laboratory experiments revealed that DC-CIK cells markedly affected the growth cycle of HepG 2 cells. Analysis showed that DC-CIK cells enhanced the gene expression of BAX and inhibited the activity of PCNA. CONCLUSIONS: Co-cultured DCs and CIK cells inhibit the proliferation and migration of liver cancer cells by down-regulating PCNA and up-regulating BAX. This approach may be an effective method to treat advanced liver cancer.
OBJECTIVES: To investigate the prognosis of advanced liver cancerpatients treated with CIK-DCs and the mechanism of apoptosis of HEPG 2 cells. METHODS: 67 patients were enrolled in the study. Peripheral blood mononuclear cells (PBMCs) were separated, of which adherent PBMCs used granulocyte 2 macrophage colony2 stimulating factor (GM2CSF), tumornecrosis factor 2α (TNF2α), and interleukin 24 (IL24) to induce DCs, which were sensitized with antigen of autologous or exogenous cancer cells to obtain Ag-DCs; suspended PBMCs used interferon 2γ (IFN2γ), IL-2, and CD 3 monoclonal antibody (CD3mAb) respectively, to induce CIK cells. DCs and CIK cells were cultured together. Flow cytometry was used to detect the phenotypes of DCs and CIK cells, and the blood retransfused into patients. Western blot and flow cytometer were used to analyze the growth cycle of HepG 2 cells and the expression of BAX and PCNA. RESULTS: No patients underwent complete remission, 5 obtained partial remission and 29 had stable disease. Of the 31 patients whose lesions could not be evaluated, 17 received effective treatment, showing that the immune response was enhanced. In vitro laboratory experiments revealed that DC-CIK cells markedly affected the growth cycle of HepG 2 cells. Analysis showed that DC-CIK cells enhanced the gene expression of BAX and inhibited the activity of PCNA. CONCLUSIONS: Co-cultured DCs and CIK cells inhibit the proliferation and migration of liver cancer cells by down-regulating PCNA and up-regulating BAX. This approach may be an effective method to treat advanced liver cancer.
Entities:
Keywords:
Bel associated protein (Bax); CDs-CIK; HEPG2 cells; liver cancer patients; proliferating cell nuclear antigen (PCNA)
Authors: A Märten; C Ziske; B Schöttker; S Renoth; S Weineck; P Buttgereit; F Schakowski; A von Rücker; T Sauerbruch; I G Schmidt-Wolf Journal: J Immunother Date: 2001 Nov-Dec Impact factor: 4.456
Authors: Bin Yang; Timothy S Johnson; Graham L Thomas; Philip F Watson; Bart Wagner; Peter N Furness; A Meguid El Nahas Journal: Kidney Int Date: 2002-10 Impact factor: 10.612
Authors: Stephan A Grupp; Eline Luning Prak; Jean Boyer; Kenyetta R McDonald; Suzanne Shusterman; Edward Thompson; Colleen Callahan; Abbas F Jawad; Bruce L Levine; Carl H June; Kathleen E Sullivan Journal: Clin Cancer Res Date: 2012-10-23 Impact factor: 12.531
Authors: D Sangiolo; G Mesiano; F Carnevale-Schianca; W Piacibello; M Aglietta; A Cignetti Journal: Expert Opin Biol Ther Date: 2009-07 Impact factor: 4.388
Authors: May C I van Schalkwyk; Sophie E Papa; Jean-Pierre Jeannon; Teresa Guerrero Urbano; James F Spicer; John Maher Journal: Hum Gene Ther Clin Dev Date: 2013-09 Impact factor: 5.032